Roivant Sciences Ltd.'s subsidiary, Dermavant Sciences Ltd., has entered into agreements to renegotiate debt obligations and reduce potential cash payments by over $300 million, with Roivant committing to contribute $195 million in exchange for convertible preferred shares.